This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
President Trump has finally signed the $717-billion 2019 defense spending bill into law — the largest allotted to U.S. defense, which has placed defense stocks in the spotlight again. The Pentagon’s base budget holds $616.9 billion, overseas contingency operations have been authorized for $69 billion and nuclear weapons programs hold $21.9 billion under the Energy Department. Also, compensation for troops has been raised by 2.
AJRD LMT MRCY HON HON ARNC UTX BA
Arconic Inc. (ARNC - Free Report) logged profits (as reported) of $120 million or 24 cents per share for the second quarter of 2018, down from $212 million or 43 cents a year ago. Barring one-time items, adjusted earnings came in at 37 cents per share for the reported quarter, which topped the Zacks Consensus Estimate of 29 cents. Arconic reported revenues of $3,573 million, up around 10% year over year, exceeding the Zacks Consensus Estimate of $3,475 million.
AVEO KMG ARNC UTX CE MEOH
Good day, ladies and gentlemen, and welcome to the Second Quarter 2018 Arconic Earnings Conference Call. My name is Jennifer, and I will be your operator for today’s call. As a reminder, today’s conference is being recorded for replay purposes.
The following slide deck was published by Arconic Inc in conjunction with their 2018 Q2 earnings call.
Arconic (ARNC - Free Report) just came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.32 per share a year ago. These figures are adjusted for non-recurring items.
(Reuters) - Aluminum products maker Arconic Inc’s (ARNC.N) revenue climbed 9.6 percent in the second quarter, led by increased demand for aircraft parts.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Arconic Inc. price-eps-surprise | Arconic Inc. Quote Arconic is focusing on cost reduction and productivity improvements across its businesses, which should lend support to its bottom line. The company gained from net cost saving in the last reported quarter and is expected to continue to benefit from its cost actions in the June quarter. However, Arconic is exposed to headwind from charges associated with higher aluminum prices, driven by LIFO (last-in, first-out) method of inventory accounting, increased processing costs and metal lag.
2018-07-27 zacks - 1
Arconic Inc. (ARNC - Free Report) is slated to release its second-quarter 2018 results before the bell on Jul 31. Arconic’s adjusted earnings of 34 cents per share for the first quarter of 2018 topped the Zacks Consensus Estimate of 32 cents, translating into a 6.3% positive surprise. Revenues rose around 8% year over year to $3,445 million in the quarter, also beating Zacks Consensus Estimate of $3,329.
EA UFS NVR ARNC TRN CC
July 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday: ** Qualcomm Inc walked away from a $44 billion deal to buy NXP Semiconductors after failing to secure Chinese regulatory approval, becoming a high profile victim of a bitter Sino-U.S. trade spat.
REG MZTSY IFL ARNC AFLYY MZTLF AFRAF IOOFF IOOFY QCOM
(Reuters) - Aluminum products maker Arconic Inc is weighing takeover approaches from at least two private-equity groups, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
BGX CG BGLF BX ARNC APO BGB
While Donald Trump’s tariffs are still in the early phases, we are already seeing the winners and losers. Just look at Alcoa (NYSE:AA). This week, the shares got crushed because of a dicey earnings report — largely due to the ill-effects of tariffs. On the news, AA stock fell by 13%. In fact, for the year so far, the return is -23%.
CSTM CENX ARNC AA
9h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
9h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
10h - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
as of ET